OBJECTIVE: To determine the annual direct, indirect and total costs and predictors of costs in patients with systemic lupus erythematosus (SLE). METHODS: One hundred and five patients with SLE completed questionnaires on health-care utilization and employment history. Predictors of costs were determined by multiple regression analyses using direct, indirect and total costs as outcome variables. Demographics, health status, disease activity, end-organ damage, social support and satisfaction with care were used as predictor variables. RESULTS: The mean annual total cost per patient was pounds sterling 7913. Direct costs were a third and indirect costs two-thirds of the total cost. Higher education level, greater disease activity and lower phy...
Systemic lupus erythematosus (SLE) is a chronic, disabling, progressive disease, with many associate...
Background: Systemic lupus Erythematosus (SLE) is a chronic multi-system autoimmune disease that can...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
Objective: To study the annual direct and indirect costs in systemic lupus erythematosus (SLE) and h...
To study the annual direct and indirect costs in systemic lupus erythematosus (SLE) and how age, dis...
We aimed to estimate the annual direct medical costs of South Korean systemic lupus erythematosus (S...
Background Systemic lupus erythematosus (SLE) has very high economic burdens on society and healthca...
OBJECTIVES: To evaluate the annual direct medical cost of managing adult systemic lupus erythematosu...
The main objectives of this study were to calculate total costs of illness and cost-driving disease ...
Objective We estimated the incremental (extra) direct medical costs of a population-based cohort of...
Background: To estimate the annual direct costs and cost-drivers associated with systemic lupus eryt...
Objectives To assess the incremental direct medical costs of a population-based cohort of incident ...
Objectives To evaluate the annual direct medical cost of managing adult systemic lupus erythematosus...
Objective A structured review of the literature was undertaken to examine the direct costs of adu...
A cohort of 306 patients was recruited. Questionnaire interview, review of medical records and clini...
Systemic lupus erythematosus (SLE) is a chronic, disabling, progressive disease, with many associate...
Background: Systemic lupus Erythematosus (SLE) is a chronic multi-system autoimmune disease that can...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
Objective: To study the annual direct and indirect costs in systemic lupus erythematosus (SLE) and h...
To study the annual direct and indirect costs in systemic lupus erythematosus (SLE) and how age, dis...
We aimed to estimate the annual direct medical costs of South Korean systemic lupus erythematosus (S...
Background Systemic lupus erythematosus (SLE) has very high economic burdens on society and healthca...
OBJECTIVES: To evaluate the annual direct medical cost of managing adult systemic lupus erythematosu...
The main objectives of this study were to calculate total costs of illness and cost-driving disease ...
Objective We estimated the incremental (extra) direct medical costs of a population-based cohort of...
Background: To estimate the annual direct costs and cost-drivers associated with systemic lupus eryt...
Objectives To assess the incremental direct medical costs of a population-based cohort of incident ...
Objectives To evaluate the annual direct medical cost of managing adult systemic lupus erythematosus...
Objective A structured review of the literature was undertaken to examine the direct costs of adu...
A cohort of 306 patients was recruited. Questionnaire interview, review of medical records and clini...
Systemic lupus erythematosus (SLE) is a chronic, disabling, progressive disease, with many associate...
Background: Systemic lupus Erythematosus (SLE) is a chronic multi-system autoimmune disease that can...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...